Antisense Technology: Selection and Delivery of Optimally Acting Antisense Oligonucleotides

References

• Akhtar S., Juliano R. L. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 1992a; 2: 139–144
   PubMedGoogle Scholar
• Akhtar S., Juliano R. L. Liposome delivery of antisense oligonucleotides: adsorption and efflux characteristics of phosphorothioate oligodeoxynucleotides. J. Controlled Release 1992b; 22: 47–56
   Web of Science ®Google Scholar
• Akhtar S., Lewis K. J. Antisense oligodeoxynucleotide delivery to cultured macrophages is improved by incorporation into sustained release biodegradable polymer microspheres. Int. J. Pharm. 1997; 151: 57–67
   Web of Science ®Google Scholar
• Akhtar S. Delivery Strategies for Antisense Oligonucleotide Therapeutics. CRC Press, Boca RatonUSA 1995
   Google Scholar
• Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 1997; 18: 12–18
   PubMed Web of Science ®Google Scholar
• Akhtar S., Rossi J. J. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?. J. Antimicrobial Chemotherapy 1996; 38: 159–165
   PubMed Web of Science ®Google Scholar
• Akhtar S., Routledge A., Patel R., Gardiner J. M. Synthesis of mono- and dimannoside phosphoramidite derivatives for solid-phase conjugation to oligonucleotides. Tet. Lett. 1995; 36: 7333–7336
   Web of Science ®Google Scholar
• Alahari S. K., Dean N. M., Fisher M., Delong R., Manoharan M., Tivel K. L., Juliano R. L. Inhibition Of Expression Of The Multidrug Resistance-Associated P-Glycoprotein By Phosphorothioate And 5'-Cholesterol-Conjugated Phosphorothioate Antisense Oligonucleotides. Mol. Pharmacol. 1996; 50: 808–819
   PubMed Web of Science ®Google Scholar
• Aoki M., Morishita R., Higaki J., Moriguchi A., Kida I., Hayashi S., Matsushita H., Kaneda Y., Ogihara T. In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. Biochem. Biophys. Res. Comm. 1997; 231: 540–545
   PubMed Web of Science ®Google Scholar
• Ballas Z. K., Rasmussen W. L., Krieg A. M. Induction Of Nk Activity In Murine And Human-Cells By CPG Motifs In Oligodeoxynucleotides And Bacterial-DNA. J. Immunol. 1996; 157: 1840–1845
   PubMed Web of Science ®Google Scholar
• Barry E. L.R., Gesek F. A., Friedman P. A. Introduction of antisense oligonucleotides into cells by permeabilisation with Streptolysin O. Biotechniques 1993; 15: 1016–1020
   PubMed Web of Science ®Google Scholar
• Bennet C. F., Chiang M-Y., Chan H., Shoemaker J. E.E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1992; 41: 1023–1033
   PubMed Web of Science ®Google Scholar
• Bennett C. F. Intracellular delivery of oligonucleotides with cationic liposomes. Delivery strategies for antisense oligonucleotide therapeutics, S. Akhtar. CRC Press, Boca Raton 1995; 223–232
   Google Scholar
• Bergan R., Connell Y., Fahmy B., Neckers L. Electroporation enhances c-myc antisense oligonucleotide efficacy. Nucl. Acids Res. 1993; 21: 3567
   PubMed Web of Science ®Google Scholar
• Bergan R., Kyle E., Connell Y., Neckers L. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res. Dev. 1995; 5: 33–38
   PubMedGoogle Scholar
• Bergan R., Hakim F., Schwartz G. N., Kyle E., Cepanda R., Szabo J. M., Fowler D., Gress R., Neckers L. Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging. Blood 1996; 88: 731–741
   PubMed Web of Science ®Google Scholar
• Bergan R., Connell Y., Fahmy B., Kyle E., Neckers L. Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucl. Acids Res. 1994; 22: 2150–2154
   PubMed Web of Science ®Google Scholar
• Berton M., Sixou S., Kravtzoff R., Dartigues C., Imbertie L., Allal C., Favre G. Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular BioVector (SMBV). Biochim. Biophys. Acta- (Mol. Cell Res) 1997; 1355: 7–19
   PubMed Web of Science ®Google Scholar
• Bertram J., Killian M., Brysch W., Schlingensiepen K. H., Kneba M. Reduction of erbB2 gene product in mamma carcinoma lines by erbB2 mRNA-specific and tyrosine kinase consenus phosphorothioate oligonucleotides. Biochem. Biophys. Res. Commun. 1994; 200: 661–667
   PubMed Web of Science ®Google Scholar
• Bielinska A., Kukowska-Latallo J. F., Johnson J., Tomalia D. A., Baker J. R. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 1994; 24: 2176–2182
   Web of Science ®Google Scholar
• Bonfils E., Depierreux C., Midoux P., Thuong N. T., Monsigny M., Roche A. C. Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. Nucleic Acids Res 1992; 20: 4621–4629
   PubMed Web of Science ®Google Scholar
• Bongartz J., Aubertin A., Milhaud G., Lebleu B. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 1994; 22: 4681–4688
   PubMed Web of Science ®Google Scholar
• Brand R. M., Iversen P. L. Iontophoretic delivery of a telomeric oligonucleotide. Pharm. Res. 1996; 13: 851–854
   PubMed Web of Science ®Google Scholar
• Carmichael E. P., Chiou H. C., Findeis M. A., Spitalny G., Merwin J. R. targeted delivery of anti-hepatitis B antisense oligonucleotides. Delivery Strategies for Antisense Oligonucleotide Therapeutics, S. Akhtar. CRC Press, Boca RatonUSA 1995; 1995
   Google Scholar
• Chavany C., Le Doan T., Couvreur P., Puisieux F., Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric particles for antisense oligonucleotides. Pharmaceutical Research 1992; 9: 441–449
   PubMed Web of Science ®Google Scholar
• Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., Helene C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 1994; 11: 1370–1378
   PubMed Web of Science ®Google Scholar
• Chin D. J., Green G. A., Zon G., Szoka F. C., Straubinger R. M. Rapid nuclear accumulation of injected oligonucleotides. The New Biologist 1990; 2: 1091–1100
   PubMedGoogle Scholar
• Chiou H. C., Tangco M. V., Levine S. M., Robertson G., Kormis K., Wu C. H., Wu G. Y. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglyco-protein-polylysine carriers. Nucleic Acids Res. 1994; 22: 5439–5446
   PubMed Web of Science ®Google Scholar
• Chollet A. Nucleosides and Nucleotides 1991; 9: 957–966
   Google Scholar
• Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci, USA 1992; 89: 7031–7035
   PubMed Web of Science ®Google Scholar
• Cortesi R., Esposito E., Menegatti E., Gambari R., Nastruzzi C. Gelatin microspheres as a new approach for the controlled delivery of synthetic oligonucleotides and PCR-generated DNA fragments. Int. J. Pharm. 1994; 105: 181–186
   Web of Science ®Google Scholar
• Coulson J. M., Akhtar S. A c-myc phosphorothioate oligonucleotide protects U87-MG cells from toxicity at high concentrations of lipofectin and steptolysin O. Pharm. Sci. 1997, in press
   Google Scholar
• Coulson J. M., Poyner D. R., Chantry A., Irwin W. J., Akhtar S. A non-antisense sequence-selective effect of a phosphorothioate oligonucleotide targeted to EGFR in A431 cells. Mol. Pharmacol 1996; 50(2)314–325
   PubMed Web of Science ®Google Scholar
• Deshpande D., Toledovelasquez D., Thakkar D., Liang W. W., Rojanasakul Y. enhanced cellular uptake of oligonucleotides by egf receptor-mediated endocytosis in A549 cells. Pharm. Res 1996; 13: 57–61
   PubMed Web of Science ®Google Scholar
• Fell P. F., Hudson A. J., Reynolds M. A., Usman N., Akhtar S. Cellular uptake properties of 2′-amino/2′-O-methyl modified chimaeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucl. Acid Drug Develop. 1997; 7: 319–326
   PubMedGoogle Scholar
• Flory C. M., Pavco P. A., Jarvis T. C., Lesch M. E., Wincott F. E., Beigelman L., Hunt S. W., Schrier D. J. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Natl. Acad. Sci, USA 1996; 86: 6454–6458
   Google Scholar
• Giles R. V., Spiller D. G., Tidd D. M. Detection of ribonuclease H-generated messenger-RNA fragments in human leukemia-cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Develop. 1995; 5: 23–31
   PubMedGoogle Scholar
• Ginobbi P., Geiser T. A., Ombres D., Citro G. Folic acid polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Antican. Res. 1997; 17: 29–35
   PubMed Web of Science ®Google Scholar
• Godard G., Boutourine A. S., Saison-Behmoaras E., Helene C. Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur. J. Biochem. 1995; 232: 404–410
   PubMedGoogle Scholar
• Grimaldi S., Lisi A., Pozzi D., Santoro N. Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Res. Virology 1997; 148: 177–180
   PubMedGoogle Scholar
• Guy-Caffey J. K., Bodepudi V., Bishop J. S., Jayaraman K., Chaudhary N. Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J. Biol. Chem. 1995; 270: 31391
   PubMed Web of Science ®Google Scholar
• Ho S. P., Britton D. H.O., Stone B. A., Beherens D. L., Leffet L. M., Hobbs F. W., Miller J. A., Trainor G. L. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selceted by mapping of RNA-accessible sites with oligonucleotide libraries. Nucl. Acids. Res. 1996; 24: 1901–1907
   PubMed Web of Science ®Google Scholar
• Hudson A. J., Lewis K. J., Rao V. M., Akhtar S. Biodegradable polymer matrices for the sustained exogenous delivery of a biologically active c-myc hammerhead ribozyme. Int. J. Pharm. 1996; 136: 23–29
   Web of Science ®Google Scholar
• Kabanov A. V., Vinogradov S. V., Ovcharenko A. V., Krivonos A. V., Melik-Nubarov N. S., Kiselev V. I., Severin E. S. A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus production and synthesis of virus-specific protiens in MDCK cells. FEBS Lett. 1990; 259: 327–330
   PubMed Web of Science ®Google Scholar
• Kreig A. M., Tonkinson J., Matson S., Zhao Q., Saxon M., Zhang L., Bhanja U., Yakubov L., Stein C. A. Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesterol moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci, USA 1993; 90: 1048–1052
   PubMed Web of Science ®Google Scholar
• Leonetti J-P., Degols G., Le Bleu B. Biological activity with oligonucleotide-poly (1-lysine) conjugtaes:mechanism of cell uptake. Biocon. Chem 1990; 1: 150–153
   Google Scholar
• Leonetti J. P., Degols G., Lebleu B. Biological activity of oligonucleotide-poly(L-lysine) conjugate: Mechanism of cell uptake. Biocon. Chem. 1990; 1: 149–153
   PubMed Web of Science ®Google Scholar
• Leonetti J. P., Mechti N., Degols G., Gagnor C., Lebleu B. Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci, USA 1991; 88: 2702–2706
   PubMed Web of Science ®Google Scholar
• Lewis J. G., Lin K-Y., Kothvale A., Flanagan W. M., Matteuchi M. D., De Prince R. B., Mook R. A., Hendren R. W., Wagner R. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynulcelotides and plasmid DNA. Proc. Natl. Acad. Sci, USA 1996; 93: 3176–3181
   PubMed Web of Science ®Google Scholar
• Lewis K. J., Irwin W. J., Akhtar S. Biodegradable poly (L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. J. Controlled Release 1995; 37(1–2)173–183
   Web of Science ®Google Scholar
• Lewis K. J., Irwin W. J., Akhtar S. Development of a sustained release biodegradable polymer system for site-specific delivery of oligonucleotides: characterization of of P(LA-GA) copolymer microspheres in vitro. J. Drug Targeting 1997, in press (this issue)
   Web of Science ®Google Scholar
• Liang W. W., Shi X. L., Deshpande D., Malanga C. J., Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim. Biophys. Acta-Biomem. 1996; 1279: 227–234
   PubMed Web of Science ®Google Scholar
• Lima W. F., Brown-Drivers V., Fox M., Hanecak R., Brucie T. W. Combinatorial screening and rational optimization of hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 1997; 272: 626–638
   PubMed Web of Science ®Google Scholar
• Lyngstadaas S. P., Risnes S., Sproat B. S., Thrane P. S., Prydz H. P. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO Journal 1995; 14: 5224–5229
   PubMed Web of Science ®Google Scholar
• Ma D. D.F., Wei A. Q. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leukemia Res. 1996; 20: 925–930
   PubMed Web of Science ®Google Scholar
• Meiden V., Irwin W. J., Akhtar S. The effects of ultrasound on the stability of Oligodeoxynucleotide in vitro. Int. J. Pharm 1997; 152: 121–125
   Google Scholar
• Milner N., Mir K. U., Southern E. M. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnol. 1997; 15: 537–541
   PubMed Web of Science ®Google Scholar
• Monia B. P., Johnston J. F., Geiger T., Muller M., Fabbro D. Antitumor-activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nature Med. 1996; 2: 668–675
   PubMed Web of Science ®Google Scholar
• Monia B. P., Sasmor H., Johnston J. F., Freier S. M., Lesnik E. A., Muller M., Geiger T., Altmann K. H., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci, USA 1997; 93: 15481–15484
   Web of Science ®Google Scholar
• Moore V., Dunnion D., Irwin W. J., Akhtar S. Interaction of lipophilic oligonucelotide conjugates with the dipeptide transporter in Caco-2 cells. Biochem. Pharmacol. 1997; 53: 1223–1228
   PubMed Web of Science ®Google Scholar
• Narayanan R., Akhtar S. Antisense Therapy. Current Opin. Oncology 1996; 8: 509–515
   PubMedGoogle Scholar
• Nestle F. O., Mitra R. S., Bennett C. F., Chan H., Nickoloff B. J. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol. 1994; 13: 569–575
   Google Scholar
• Noonberg S. B., Garovoy M. R., Hunt C. A. Characteristics of oligonucleotide uptake in human ketainocyte cultures. J. Invest. Dermatol. 1993; 101: 727–731
   PubMed Web of Science ®Google Scholar
• Oldenburg K. R., Vo K. T., Smith G. A., Selick H. E. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J. Pharm. Sci. 1995; 84: 915–921
   PubMed Web of Science ®Google Scholar
• Partridge W. M., Boado R. J. Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein. FEBS lett. 1991; 288: 30–32
   PubMed Web of Science ®Google Scholar
• Pichon C., Arar K., Stewart A. J., Dodon M. D., Gazzolo L., Courtoy P. J., Mayer R., Monsigny M., Roche A. C. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. Mol. Pharmacol. 1997; 51: 431–438
   PubMed Web of Science ®Google Scholar
• Rojanasakul Y., Weissman D. N., Shi X. L., Castranova V., Ma J. K.H., Liang W. W. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages. J. Biol. Chem. 1997; 272: 3910–3914
   PubMed Web of Science ®Google Scholar
• Schwab C., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed onto polycyanoacrylate nanoparticles specifically inhibit mutated Haras mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. AcadSci (USA) 1994; 91: 10460–10464
   PubMed Web of Science ®Google Scholar
• Shea R. G., Marsters J. C., Bischofberger N. Synthesis, hybridisation properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucl. Acids Res. 1990; 18: 3777–3783
   PubMed Web of Science ®Google Scholar
• Slepushkin V. A., Simoes S., Dazin P., Newman M. S., Guo L. S., de Lima M. C.P., Duzgunes N. Sterically stabilized pH-sensitive liposomes—Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem 1997; 272: 2382–2388
   PubMed Web of Science ®Google Scholar
• Southern E. M. DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. Trends Genet. 1996; 12: 110–114
   PubMed Web of Science ®Google Scholar
• Southern E. M., Case-Green S. C., Elder J., Johnson M., Mir K., Wang L., Willimas J. C. Arrays of complementary oligonucleotides for analysing the hybridization behaviour of nucleic acids. Nucl. Acids Res. 1994; 22: 1368–1373
   PubMed Web of Science ®Google Scholar
• Spiller D. G., Tidd D. M. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia-cells with streptolysin-O. Antisense Res. Develop. 1995; 5: 13–21
   PubMedGoogle Scholar
• Stewart A. J., Pichon C., Meunier L., Midoux P., Monsigny M., Roche A. C. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine. Mol. Pharmacol. 1996; 50: 1487–1494
   PubMed Web of Science ®Google Scholar
• Symons R. Small catalytic RNAs. Ann. Rev. Biochem. 1992; 62: 641–671
   Google Scholar
• Thierry A., Takle G. B. Liposomes as delivery system for antisense and ribozyme compounds, in Delivery Strategies for Antisense Oligonucleotide Therapeutics, S. Akhtar. CRC Press, Boca RatonUSA 1995; 1995
   Google Scholar
• Vlassov V. V., Nechaeva M. V., Karamyshev V. N., Yakubov L. A. Iontophoretic delivery of oligonucleotide derivatives into mouse tumour. Antisense Res Develop. 1994; 4: 291–293
   PubMedGoogle Scholar
• Walker I., Irwin W. J., Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm. Res. 1995; 12: 1548–1553
   PubMed Web of Science ®Google Scholar
• Wang S., Lee R. J., Cauchon G., Gorenstein D. G., Low P. S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci USA 1995; 92: 3318–3322
   PubMed Web of Science ®Google Scholar
• Williams S. A., Chang L., Buzby J. S., Suen Y., Cairo M. S. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Leukemia 1996; 10: 1980–1989
   PubMed Web of Science ®Google Scholar
• Wu-Pong S., Weiss T. L., Hunt C. A. Calcium Dependent Cellular uptake of a c-yc antisense oligonucleotide. Cell. Mol. Biol. 1994; 40: 843–850
   PubMed Web of Science ®Google Scholar
• Wyman T. B., Nicol F., Zelphati O., Scaria P. V., Plank C., Szoka F. C. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997; 36: 3008–3017
   PubMed Web of Science ®Google Scholar
• Yamada K., Moriguchi A., Morishita R., Aoki M., Nakamura Y., Mikami H., Oshima T., Ninomiya M., Kaneda Y., Higaki J., Ogihara T. Efficient Oligonucleotide Delivery using the HVJ-Liposome Method in the Central-Nervous-System. American J. Physiol. (Regul. Integ. Comp. Physiol.) 1996; 40: R1212–R1220
   Google Scholar
• Yamamoto T., Yamamoto S., Kataoka T., Tokunaga T. Antisense Res. Dev. 1994; 4: 119–122
   PubMedGoogle Scholar
• Yazaki T., Ahmad S., Chahlavi A., Zylberkatz E., Dean N. M., Rabkin S. D., Martuza R. L., Glazer R. I. Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein-Kinase C-Alpha Phosphorothioate Oligo-deoxynucleotide. Mol. Pharmacol. 1996; 50: 236–242
   PubMed Web of Science ®Google Scholar
• Zelphati O., Szoka F. C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad Sci., USA 1996; 93: 11943–11948
   Google Scholar
• Zewert T. E., Pliquett U. F., Langer R., Weaver J. C. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res Commun. 1995; 212: 286–292
   PubMed Web of Science ®Google Scholar